Impact of long-term steroid therapy on epicardial and pericardial fat deposition: A cardiac MRI study

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Kitterer, Daniel ^a   Latus, Joerg ^a   Henes, Joerg ^b   Birkmeier, Stefan ^a   Backes, Maik ^a   Braun, Niko ^a   Sechtem, Udo ^a   Dominik Alscher, M ^a   Mahrholdt, Heiko ^a   Greulich, Simon ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cardiac MRI; Epicardial fat; Pericardial fat; Rheumatic disorder; Steroid therapy

Indexed keywords

PREDNISONE; GLUCOCORTICOID;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; EPICARDIAL FAT; EPICARDIUM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LIPID STORAGE; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PERICARDIAL FAT; PERICARDIUM; RHEUMATIC DISEASE; AGED; CASE CONTROL STUDY; CINE MAGNETIC RESONANCE IMAGING; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RHEUMATIC DISEASES; TIME FACTOR;

ADIPOSE TISSUE; ADIPOSITY; ADULT; AGED; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; PERICARDIUM; PREDICTIVE VALUE OF TESTS; PREDNISONE; RHEUMATIC DISEASES; TIME FACTORS;

EID: 84942609403     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0289-x     Document Type: Article

References (39)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948-54. doi: 10.1161/CIRCULATIONAHA.109.192666.
2. TaskForce M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi: 10.1093/eurheartj/eht296.
3. Nyman K, Graner M, Pentikainen MO, Lundbom J, Hakkarainen A, Siren R, et al. Cardiac steatosis and left ventricular function in men with metabolic syndrome. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2013;15:103. doi: 10.1186/1532-429X-15-103.
4. Ding J, Hsu FC, Harris TB, Liu Y, Kritchevsky SB, Szklo M, et al. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr. 2009;90(3):499-504. doi: 10.3945/ajcn.2008.27358.
5. Tamarappoo B, Dey D, Shmilovich H, Nakazato R, Gransar H, Cheng VY, et al. Increased pericardial fat volume measured from noncontrast CT predicts myocardial ischemia by SPECT. JACC Cardiovasc Imaging. 2010;3(11):1104-12. doi: 10.1016/j.jcmg.2010.07.014.
6. Aslanabadi N, Salehi R, Javadrashid A, Tarzamni M, Khodadad B, Enamzadeh E, et al. Epicardial and pericardial fat volume correlate with the severity of coronary artery stenosis. J Cardiovasc Thorac Res. 2014;6(4):235-9. doi: 10.15171/jcvtr.2014.018.
7. Cheng VY, Dey D, Tamarappoo B, Nakazato R, Gransar H, Miranda-Peats R, et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc Imaging. 2010;3(4):352-60. doi: 10.1016/j.jcmg.2009.12.013.
8. Mahabadi AA, Berg MH, Lehmann N, Kalsch H, Bauer M, Kara K, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol. 2013;61(13):1388-95. doi: 10.1016/j.jacc.2012.11.062.
9. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482-9c. doi: 10.1093/eurheartj/ehu403.
10. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E, Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized P. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2013;15:91. doi: 10.1186/1532-429X-15-91.
11. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250-8. doi: 10.1161/01.CIR.0000118493.13323.81.
12. Graner M, Siren R, Nyman K, Lundbom J, Hakkarainen A, Pentikainen MO, et al. Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J Clin Endocrinol Metab. 2013;98(3):1189-97. doi: 10.1210/jc.2012-3190.
13. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-24. doi: 10.1136/ard.2008.092163.
14. Furst DE, Saag KG. Determinants of glucocorticoid dosing. Up to date 2015. 2013. http://www.uptodate.com/contents/determinants-of-glucocorticoiddosing?source=search_result&search=glucocorticoid&selectedTitle=4~150. Accessed 15 Sept 2015.
15. Kim SH, Chung JH, Kwon BJ, Song SW, Choi WS. The associations of epicardial adipose tissue with coronary artery disease and coronary atherosclerosis. Int Heart J. 2014;55(3):197-203.
16. Chen O, Sharma A, Ahmad I, Bourji N, Nestoiter K, Hua P, et al. Correlation between pericardial, mediastinal, and intrathoracic fat volumes with the presence and severity of coronary artery disease, metabolic syndrome, and cardiac risk factors. Eur Heart J Cardiovasc Imaging. 2015;16(1):37-46. doi: 10.1093/ehjci/jeu145.
17. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med J Br Diabet Assoc. 2006;23(5):469-80. doi: 10.1111/j.1464-5491.2006.01858.x.
18. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-6. doi: 10.1002/art.21984.
19. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728-9. doi: 10.2337/dc06-1499.
20. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97-101.
21. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab. 1986;62(2):275-9. doi: 10.1210/jcem-62-2-275.
22. Whitworth JA. Studies on the mechanisms of glucocorticoid hypertension in humans. Blood Press. 1994;3(1-2):24-32.
23. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol. 2004;61(6):768-77. doi: 10.1111/j.1365-2265.2004.02168.x.
24. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764-70.
25. Gorter PM, van Lindert AS, de Vos AM, Meijs MF, van der Graaf Y, Doevendans PA, et al. Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis. 2008;197(2):896-903. doi: 10.1016/j.atherosclerosis.2007.08.016.
26. Macfarlane DP, Raubenheimer PJ, Preston T, Gray CD, Bastin ME, Marshall I, et al. Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver. Am J Physiol Gastrointest Liver Physiol. 2014;307(7):G760-8. doi: 10.1152/ajpgi.00030.2014.
27. Ichikawa R, Daimon M, Miyazaki T, Kawata T, Miyazaki S, Maruyama M, et al. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:38. doi: 10.1186/1475-2840-12-38.
28. Yuen KC, Roberts CT Jr, Frystyk J, Rooney WD, Pollaro JR, Klopfenstein BJ, et al. Short-term, low-dose GH therapy improves insulin sensitivity without modifying cortisol metabolism and ectopic fat accumulation in adults with GH deficiency. J Clin Endocrinol Metab. 2014;99(10):E1862-9. doi: 10.1210/jc.2014-1532.
29. Geer EB, Shen W, Gallagher D, Punyanitya M, Looker HC, Post KD, et al. MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease. Clin Endocrinol. 2010;73(4):469-75. doi: 10.1111/j.1365-2265.2010.03829.x.
30. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol/Eur Fed Endocr Soc. 2003;149(6):561-7.
31. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerario AC, et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab. 1995;80(9):2791-4. doi: 10.1210/jcem.80.9.7673425.
32. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-77.
33. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta. 2000;1500(1):88-96.
34. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res. 2007;101(1):27-39. doi: 10.1161/CIRCRESAHA.107.151621.
35. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108(20):2460-6. doi: 10.1161/01.CIR.0000099542.57313.C5.
36. Taguchi R, Takasu J, Itani Y, Yamamoto R, Yokoyama K, Watanabe S, et al. Pericardial fat accumulation in men as a risk factor for coronary artery disease. Atherosclerosis. 2001;157(1):203-9.
37. Picard FA, Gueret P, Laissy JP, Champagne S, Leclercq F, Carrie D, et al. Epicardial adipose tissue thickness correlates with the presence and severity of angiographic coronary artery disease in stable patients with chest pain. PLoS One. 2014;9(10):e110005. doi: 10.1371/journal.pone.0110005.
38. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560-7. doi: 10.1136/ard.2007.072157.
39. Oyama N, Goto D, Ito YM, Ishimori N, Mimura R, Furumoto T, et al. Single-slice epicardial fat area measurement: do we need to measure the total epicardial fat volume? Jpn J Radiol. 2011;29(2):104-9. doi: 10.1007/s11604-010-0524-z.